Choosing a Probiotic for SIBO and IBS: Strain-Level Decision Logic

Small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) overlap clinically but require different probiotic logic. In SIBO, the small intestine already has too many bacteria; adding more without thinking can worsen symptoms. In IBS, the question is which strain matches the predominant symptom pattern. Most consumer probiotic marketing collapses both conditions into a single "gut health" pitch, which is why people often pick wrong.

For IBS, the strain-level evidence is what counts

Genus and species (Lactobacillus, Bifidobacterium) tell you almost nothing about expected clinical effect. Strain-level data is what supports a recommendation. The strains with the strongest IBS trial record include Bifidobacterium infantis 35624 (Align), which improved abdominal pain and bloating in trials of mostly female IBS patients; Bifidobacterium longum NCC3001, which has multiple trials in IBS with comorbid depression; and Lactobacillus plantarum 299v, which reduced pain and bloating across several controlled trials.

Saccharomyces boulardii CNCM I-745 has the cleanest data for diarrhea-predominant IBS and for antibiotic-associated diarrhea, including in patients undergoing IBS-related antibiotic treatments. Multi-strain consortia such as VSL#3 and its successor Visbiome have evidence in pouchitis and ulcerative colitis maintenance, with weaker IBS data.

For SIBO, the picture is more complicated

Counterintuitively, several SIBO trials have shown benefit from probiotic supplementation, but the strain choice is critical and the mechanism is different. The most-replicated SIBO finding involves Bacillus species (B. coagulans, B. subtilis, B. clausii) and Saccharomyces boulardii — spore-formers and yeasts that pass through the proximal gut without colonizing it. They appear to act as competitive antagonists against the overgrowth bacteria, not as colonizers themselves.

Lactic acid bacteria (most marketed probiotics) are more variable in SIBO. Some patients improve; some report worsening of hydrogen and methane production, particularly with hydrogen-dominant SIBO. The clinical pattern: try Bacillus or Saccharomyces first in confirmed SIBO; if a lactic-acid probiotic worsens symptoms, stop it and do not interpret that as a sign you need more.

Reading the label so you actually get what was studied

Strain identifier is the most important thing on a probiotic label. Look for the specific designation, not just the species: "L. plantarum 299v" or "B. infantis 35624" or "S. boulardii CNCM I-745". Generic "L. plantarum" or "Bifidobacterium infantis" without a strain number is not the trial-studied product.

CFU count matters less than people assume, but watch for two things: the count should be guaranteed through the end of shelf life (not at manufacture), and the studied trial dose should be on the label per daily serving (usually 1–10 billion CFU for the IBS strains listed, 5–10 billion for S. boulardii). Refrigeration requirements vary by strain; spore-formers like Bacillus and the yeast S. boulardii are stable at room temperature, while many Lactobacillus and Bifidobacterium strains require refrigeration to maintain viability.

Bottom line

For IBS, match strain to symptom: Bifidobacterium infantis 35624 for pain/bloating, Bifidobacterium longum NCC3001 if mood symptoms cluster with IBS, Lactobacillus plantarum 299v for general IBS symptoms, S. boulardii for diarrhea-predominant. For SIBO, prefer spore-formers (Bacillus species) and Saccharomyces boulardii over lactic-acid bacteria, and stop any probiotic that worsens symptoms rather than reflexively switching. Insist on strain-level naming on the label or you are not buying the studied product.